Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.

Autor: Efficace F; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy. f.efficace@gimema.it., Mahon FX; Bergonié Cancer Institute, INSERM UMR1312 Inserm, University of Bordeaux, Bordeaux, France., Richter J; Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., Piciocchi A; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy., Cipriani M; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy.; Department of Statistical Sciences, Sapienza University of Rome, Rome, Italy., Nicolini FE; Centre Léon Bérard, Service d'Hématologie Clinique & INSERM U1052 CRCL, Lyon, France., Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Zackova D; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Janssen JJWM; Department of Hematology, Radboud UMC, Nijmegen, The Netherlands., Panayiotidis P; Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece., Vestergaard H; Department of Haematology, Odense University Hospital, Odense, Denmark., Koskenvesa P; Hematology Research Unit Helsinki and HUS Cancer Center, Hematology Line, Helsinki, Finland., Almeida A; Faculdade de Medicina, Universidade Católica Portuguesa, Lisbon, Portugal.; Hospital da Luz, Lisbon, Portugal., Hjorth-Hansen H; St Olavs Hospital HF, Trondheim, Norway., Martinez-Lopez J; Hospital 12 de Octubre, CNIO, i+12, Department of Medicine Univ. Complutense, Madrid, Spain., Olsson-Strömberg U; Department of Medical Sciences, Uppsala University and Hematology Section, Uppsala University Hospital, Uppsala, Sweden., Hochhaus A; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany., Berger MG; CHU Clermont-Ferrand, Hematology department, and EA 7453 CHELTER, University Clermont Auvergne, Clermont-Ferrand, France., Etienne G; Institut Bergonié, département d'hématologie, Bordeaux, France.; France Intergroupe de la leucémie myéloïde chronique Fi-LMC, Lyon, France., Klamova H; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Faber E; Department of Hemato-oncology, Faculty Hospital and Faculty of Medicine and Dentistry, Palacký University, Olomouc, Olomouc, Czech Republic., Rousselot P; Centre Hospitalier de Versailles, Department of Haematology, University Versailles Paris-Saclay, Le Chesnay, France., Pfirrmann M; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, LMU München, München, Germany., Saussele S; Medical Clinic, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2024 Aug; Vol. 38 (8), pp. 1722-1730. Date of Electronic Publication: 2024 Jul 10.
DOI: 10.1038/s41375-024-02341-4
Abstrakt: Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and ≥70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: